vTv Therapeutics (VTVT) Capital Expenditures (2014 - 2017)

vTv Therapeutics has disclosed Capital Expenditures across 3 years of filings, most recently posting $18000.0 for Q4 2017.

• Capital Expenditures for Q4 2017 came in at $18000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $18000.0 (changed N/A YoY), and the FY2022 annual result was $21000.0, changed N/A from the prior year.
• Capital Expenditures came in at $18000.0 for Q4 2017 at vTv Therapeutics, down from $39000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $62000.0 in Q4 2015 to a low of -$2000.0 in Q4 2014.
• The 3-year median for Capital Expenditures is $13500.0 (2014), against an average of $21000.0.
• Peak annual rise in Capital Expenditures reached 3200.0% in 2015, while the deepest fall reached 0.0% in 2015.
• vTv Therapeutics' Capital Expenditures stood at -$2000.0 in 2014, then jumped by 3200.0% to $62000.0 in 2015, then tumbled by 70.97% to $18000.0 in 2017.
• The last three Capital Expenditures figures came in at $18000.0 (Q4 2017), $39000.0 (Q1 2017), and $62000.0 (Q4 2015), per Business Quant data.